CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Ulipristal versus Levonorgestrel for Emergency Contraception: A Review of Comparative Cost Effectiveness

Last updated: February 12, 2019
Project Number: RC1072-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What is the comparative cost-effectiveness of ulipristal versus levonorgestrel for use as emergency contraception?

Key Message

Two identified economic studies provided evidence that ulipristal was the cost-effective emergency contraception alternative to levonorgestrel. No studies conducted subgroup analysis based on body mass index.